Caladrius Biosciences Inc
1.47 %
-4.59 %
Yet to be announced
Company Overview
Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies to treat cardiovascular and other diseases. The company's primary focus is on developing innovative treatments using cell technologies, particularly in cardiovascular medicine.
Revenue Sources
PassThe company is currently in pre-revenue stage, focusing on research and development of cell therapies. As such, there is no revenue to evaluate for haram sources. Given the company's focus on developing therapeutic treatments, their intended business model appears to be halal-compliant.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2025 | $70,000 | $4.94m | - | - | 0.00% | 0.00% |
| Dec. 31, 2024 | $1.0m | $5.95m | - | - | 0.00% | 0.00% |
Looking at the most recent four quarters of financial data, the company reports zero interest income and zero interest expense. Additionally, since the company is still in pre-revenue research and development phase, the interest ratio tests are not applicable at this stage.
Operational Ethics
PassBased on available information from SEC filings and company materials, there is no evidence of any ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Comments